21352464

Source:http://linkedlifedata.com/resource/pubmed/id/21352464

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0011860, umls-concept:C0019018, umls-concept:C0030705, umls-concept:C0087111, umls-concept:C0332307, umls-concept:C0441994, umls-concept:C0442027, umls-concept:C1442465, umls-concept:C2746078, umls-concept:C2917389
pubmed:issue	6
pubmed:dateCreated	2011-4-21
pubmed:abstractText	To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of linagliptin in patients with type 2 diabetes mellitus (T2DM).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100883645
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose, http://linkedlifedata.com/resource/pubmed/chemical/Dipeptidyl-Peptidase IV Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobin A, Glycosylated, http://linkedlifedata.com/resource/pubmed/chemical/Hypoglycemic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Linaclotide Acetate, http://linkedlifedata.com/resource/pubmed/chemical/Placebos, http://linkedlifedata.com/resource/pubmed/chemical/Purines, http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines
pubmed:status	MEDLINE
pubmed:month	Jun
pubmed:issn	1463-1326
pubmed:author	pubmed-author:DugiK AKA, pubmed-author:ForstTT, pubmed-author:Graefe-ModyUU, pubmed-author:RingAA, pubmed-author:RitzhauptAA, pubmed-author:Uhlig-LaskeBB
pubmed:copyrightInfo	© 2011 Blackwell Publishing Ltd.
pubmed:issnType	Electronic
pubmed:volume	13
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	542-50
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:21352464-Adult, pubmed-meshheading:21352464-Aged, pubmed-meshheading:21352464-Blood Glucose, pubmed-meshheading:21352464-Diabetes Mellitus, Type 2, pubmed-meshheading:21352464-Dipeptidyl-Peptidase IV Inhibitors, pubmed-meshheading:21352464-Dose-Response Relationship, Drug, pubmed-meshheading:21352464-Double-Blind Method, pubmed-meshheading:21352464-Hemoglobin A, Glycosylated, pubmed-meshheading:21352464-Humans, pubmed-meshheading:21352464-Hypoglycemic Agents, pubmed-meshheading:21352464-Male, pubmed-meshheading:21352464-Middle Aged, pubmed-meshheading:21352464-Placebos, pubmed-meshheading:21352464-Postprandial Period, pubmed-meshheading:21352464-Purines, pubmed-meshheading:21352464-Quinazolines, pubmed-meshheading:21352464-Treatment Outcome, pubmed-meshheading:21352464-Young Adult
pubmed:year	2011
pubmed:articleTitle	The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
pubmed:affiliation	Institut für Klinische Forschung und Entwicklung GmbH, Mainz, Germany.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II